Roche extended its KRAS lung cancer strategy with Phase 3 data indicating its KRAS G12C inhibitor divarasib outperformed marketed comparators in a head-to-head trial. In parallel, Roche’s divarasib program is positioned to challenge Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, with early-market focus shifting to survival endpoints and label-readiness as additional results land. The competitive bar for KRAS-driven NSCLC continues rising as cross-trial comparisons are increasingly tied to payer and guideline adoption decisions.